Cargando…

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability

Multiple Sclerosis (MS) is the most common chronic inflammatory and neurodegenerative disease of the central nervous system (CNS), which can lead to severe cognitive impairment over time. Magnetic resonance imaging (MRI) is currently the best available biomarker to track MS pathophysiology in vivo a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Has Silemek, Arzu Ceylan, Fischer, Lukas, Pöttgen, Jana, Penner, Iris-Katharina, Engel, Andreas K., Heesen, Christoph, Gold, Stefan M., Stellmann, Jan-Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997626/ https://www.ncbi.nlm.nih.gov/pubmed/32014828 http://dx.doi.org/10.1016/j.nicl.2020.102177

Ejemplares similares

Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity
por: Has Silemek, Arzu C., et al.
Publicado: (2021)

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS
por: Stellmann, Jan‐Patrick, et al.
Publicado: (2016)

Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis—a randomized controlled trial
por: Baquet, Lisa, et al.
Publicado: (2018)

Distinct Functional Connectivity Signatures of Impaired Social Cognition in Multiple Sclerosis
por: Golde, Sabrina, et al.
Publicado: (2020)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
por: Migliore, S., et al.
Publicado: (2017)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting
por: von Gumberz, Johanna, et al.
Publicado: (2016)

Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis
por: Gschwind, Markus, et al.
Publicado: (2016)

Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial
por: Stellmann, Jan-Patrick, et al.
Publicado: (2020)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals
por: Zhai, Yuyang, et al.
Publicado: (2020)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Impairment and restrictions in possibly benign multiple sclerosis
por: Schaefer, Laura Melanie, et al.
Publicado: (2019)

Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
por: Giordano, Andrea, et al.
Publicado: (2018)

Contribution of Gray Matter Atrophy and White Matter Damage to Cognitive Impairment in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients
por: Bernabéu-Sanz, Ángela, et al.
Publicado: (2021)

Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients
por: Stellmann, JP, et al.
Publicado: (2015)

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID-19 era
por: Toscano, Simona, et al.
Publicado: (2022)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
por: Stürner, Klarissa Hanja, et al.
Publicado: (2020)

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials
por: Lavery, Amy M., et al.
Publicado: (2014)

Intrinsic Functional Plasticity of the Thalamocortical System in Minimally Disabled Patients with Relapsing-Remitting Multiple Sclerosis
por: Zhou, Fuqing, et al.
Publicado: (2016)

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability
por: Siotto, Mariacristina, et al.
Publicado: (2019)

Correction to: Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID‑19 era
por: Toscano, Simona, et al.
Publicado: (2022)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
por: Bellmann-Strobl, Judith, et al.
Publicado: (2021)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis
por: Caligiuri, Maria Eugenia, et al.
Publicado: (2014)

The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Functional connectivity dynamics reflect disability and multi-domain clinical impairment in patients with relapsing-remitting multiple sclerosis
por: Romanello, Amy, et al.
Publicado: (2022)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022)

Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)—Results of a Pilot Randomized Controlled Trial
por: Heinrich, Inga, et al.
Publicado: (2021)

Chronic insomnia remitting after maxillomandibular advancement for mild obstructive sleep apnea: a case series
por: Proothi, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gr8ugre0er543dcpegjs78749k